At a glance
ClinicalIndex Comparison RecordPhase 1Completed· 72 enrolled
Drug / intervention
MMV688533drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.
Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
A Two-part, Phase 1 Study to Assess the Safety, Tolerability, and Pharmacokinetic Profile of Ascending Single Doses of MMV533, Including a Pilot Food Evaluation in Healthy Participants.
In Brief
A Phase 1 clinical trial evaluating MMV688533 for Malaria. Completed, enrolled 72 participants across 1 site.
Detailed Summary
Phase 1, single -centre study in 2 parts. The study designs for each part are well established for first-in-human studies and are appropriate to assess safety, tolerability and preliminary pharmacokinetics.
Study Details
Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsMalaria
CountriesAustralia
CollaboratorsNucleus Network Ltd, Southern Star Research
Timeline
Phase 1CompletedFinished
202120222023202420252026
First PostedMar 2020
Enrollment StartAug 2020
Primary CompletionSep 2022
TodayJul 2026
First PostedMar 26, 2020
Enrollment StartAug 12, 2020
Primary CompletionSep 27, 2022
TodayJul 2, 2026
Enrollment to primary: 2.1 yearsPosted 6.3 years ago
Interventions
MMV688533drug
Investigational medicinal product